Daniel James Hodson

Daniel James Hodson

Auto-generated profile, based on publicly available information

Daniel James Hodson

Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 April 2018 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
RSRoland Schmitz
Roland Schmitz
GWGeorge W. Wright
George W. Wright
DHDa Wei Huang
Da Wei Huang
CJCalvin A. Johnson
Calvin A. Johnson
JPJames D. Phelan
James D. Phelan
LSLouis M. Staudt
Louis M. Staudt
Diffuse large B-cell lymphomas (DLBCLs) are phenotypically and genetically heterogeneous. Gene-expression profiling has identified subgroups of DLBCL (activated B-cell–like [ABC], germinal-center B-cell–like [GCB], and unclassified) according to cell of origin that are associated with a differential response to chemotherapy and targeted agents. We sought to extend these findings by identifying genetic subtypes of DLBCL based on shared genomic abnormalities and to uncover therapeutic vulnerabilities based on tumor genetics. We studied 574 DLBCL biopsy samples using exome and transcriptome sequencing, array-based DNA copy-number analysis, and targeted amplicon resequencing of 372 genes to identify genes with recurrent aberrations. We developed and implemented an algorithm to discover genetic subtypes based on the co-occurrence of genetic alterations. We identified four prominent genetic subtypes in DLBCL, termed MCD (based on the co-occurrence of MYD88L265P and CD79B mutations), BN2 (based on BCL6 fusions and NOTCH2 mutations), N1 (based on NOTCH1 mutations), and EZB (based on EZH2 mutations and BCL2 translocations). Genetic aberrations in multiple genes distinguished each genetic subtype from other DLBCLs. These subtypes differed phenotypically, as judged by differences in gene-expression signatures and responses to immunochemotherapy, with favorable survival in the BN2 and EZB subtypes and inferior outcomes in the MCD and N1 subtypes. Analysis of genetic pathways suggested that MCD and BN2 DLBCLs rely on “chronic active” B-cell receptor signaling that is amenable to therapeutic inhibition. We uncovered genetic subtypes of DLBCL with distinct genotypic, epigenetic, and clinical characteristics, providing a potential nosology for precision-medicine strategies in DLBCL. (Funded by the Intramural Research Program of the National Institutes of Health and others.)

12 August 2012 in Nature
Verified
Journal Article
Closed access
PDF file
RSRoland Schmitz
Roland Schmitz
RYRyan M. Young
Ryan M. Young
MCMichele Ceribelli
Michele Ceribelli
SJSameer Jhavar
Sameer Jhavar
WXWenming Xiao
Wenming Xiao
LSLouis M. Staudt
Louis M. Staudt

14 May 2020 in Blood
Verified
Journal Article
Open access
PDF file
SLStuart E. Lacy
Stuart E. Lacy
SBSharon L. Barrans
Sharon L. Barrans
PBPhilip A. Beer
Philip A. Beer
DPDaniel Painter
Daniel Painter
ASAlexandra G. Smith
Alexandra G. Smith
DHDaniel J. Hodson
Daniel J. Hodson
Based on the profile of genetic alterations occurring in tumor samples from selected diffuse large B-cell lymphoma (DLBCL) patients, 2 recent whole-exome sequencing studies proposed partially overlapping classification systems. Using clustering techniques applied to targeted sequencing data derived from a large unselected population-based patient cohort with full clinical follow-up (n = 928), we investigated whether molecular subtypes can be robustly identified using methods potentially applicable in routine clinical practice. DNA extracted from DLBCL tumors diagnosed in patients residing in a catchment population of ∼4 million (14 centers) were sequenced with a targeted 293-gene hematological-malignancy panel. Bernoulli mixture-model clustering was applied and the resulting subtypes analyzed in relation to their clinical characteristics and outcomes. Five molecular subtypes were resolved, termed MYD88, BCL2, SOCS1/SGK1, TET2/SGK1, and NOTCH2, along with an unclassified group. The subtypes characterized by genetic alterations of BCL2, NOTCH2, and MYD88 recapitulated recent studies showing good, intermediate, and poor prognosis, respectively. The SOCS1/SGK1 subtype showed biological overlap with primary mediastinal B-cell lymphoma and conferred excellent prognosis. Although not identified as a distinct cluster, NOTCH1 mutation was associated with poor prognosis. The impact of TP53 mutation varied with genomic subtypes, conferring no effect in the NOTCH2 subtype and poor prognosis in the MYD88 subtype. Our findings confirm the existence of molecular subtypes of DLBCL, providing evidence that genomic tests have prognostic significance in non-selected DLBCL patients. The identification of both good and poor risk subtypes in patients treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) clearly show the clinical value of the approach, confirming the need for a consensus classification.

11 July 2010 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
DHDaniel J Hodson
Daniel J Hodson
MJMichelle L Janas
Michelle L Janas
AGAlison Galloway
Alison Galloway
SBSarah E Bell
Sarah E Bell
SASimon Andrews
Simon Andrews
MTMartin Turner
Martin Turner

22 April 2016 in Science
Verified
Journal Article
Closed access
PDF file
AGAlison Galloway
Alison Galloway
ASAlexander Saveliev
Alexander Saveliev
SŁSebastian Łukasiak
Sebastian Łukasiak
DHDaniel J. Hodson
Daniel J. Hodson
DBDaniel Bolland
Daniel Bolland
MTMartin Turner
Martin Turner
Reducing the risk of rearrangement: As lymphocytes develop, they rearrange their antigen receptor genes and proliferate extensively, potentially putting their genomes at risk. Galloway et al. found that two RNA-binding proteins, ZFP36L1 and ZFP36L2, ensure careful entry and exit into the cell cycle. This helps developing B lymphocytes maintain their genomic integrity. Mice deficient in ZFP36L1 and ZFP36L2 exhibited a profound block in B cell development. ZFP36L1 and ZFP36L2 suppress mRNAs that help B cells progress through the cell cycle, ensuring that cells can enter quiescence and keep their genomes safe when they undergo the risky process of rearranging their antigen receptors. Science , this issue p. 453

24 November 2022 in Blood
Verified
Journal Article
Open access
PDF file
LLLaurence de Leval
Laurence de Leval
AAAsh A Alizadeh
Ash A Alizadeh
PBP. Leif Bergsagel
P. Leif Bergsagel
ECElias Campo
Elias Campo
ADAndrew Davies
Andrew Davies
DSDavid W. Scott
David W. Scott
With the introduction of large-scale molecular profiling methods and high-throughput sequencing technologies, the genomic features of most lymphoid neoplasms have been characterized at an unprecedented scale. Although the principles for the classification and diagnosis of these disorders, founded on a multidimensional definition of disease entities, have been consolidated over the past 25 years, novel genomic data have markedly enhanced our understanding of lymphomagenesis and enriched the description of disease entities at the molecular level. Yet, the current diagnosis of lymphoid tumors is largely based on morphological assessment and immunophenotyping, with only few entities being defined by genomic criteria. This paper, which accompanies the International Consensus Classification of mature lymphoid neoplasms, will address how established assays and newly developed technologies for molecular testing already complement clinical diagnoses and provide a novel lens on disease classification. More specifically, their contributions to diagnosis refinement, risk stratification, and therapy prediction will be considered for the main categories of lymphoid neoplasms. The potential of whole-genome sequencing, circulating tumor DNA analyses, single-cell analyses, and epigenetic profiling will be discussed because these will likely become important future tools for implementing precision medicine approaches in clinical decision making for patients with lymphoid malignancies.